Replies to post #24184 on RespireRx Pharmaceuticals Inc (RSPI)

[atheroprevent]

Neuro, I do remember several of your earlier posts with references to LLY indicating superior capability in ampa area 2-3 years ago. That was followed by LLY overturning some of COR's European patent rights in Jan 08?

BTW, while we all know what the FDA did not approve, here from Medscape, is what they did allow in 2008. The new not "me to" drugs are in the smaller Table 2, with only 4 classes of drugs.

http://www.medscape.com/viewarticle/589051_Tables#T1